Targeting Angiogenesis in Colorectal Carcinoma

Area of Science:

• Oncology
• Vascular Biology

Background:

• Neo-angiogenesis is crucial in colorectal cancer, driven by vascular endothelial growth factor (VEGF) signaling pathways.
• Anti-angiogenic therapies have significantly improved colorectal cancer prognosis over the last 15 years.
• Bevacizumab and other agents like ramucirumab and aflibercept demonstrate the success of continuous anti-angiogenic blockade.

Purpose of the Study:

• To review the role of anti-angiogenic therapies in colorectal cancer.
• To discuss the efficacy and sequencing of current anti-angiogenic agents.
• To highlight the need for future research in biomarker discovery and novel drug development.

Main Methods:

• Review of clinical trial data and literature on anti-angiogenic therapies in colorectal cancer.
• Analysis of the efficacy and sequencing strategies of approved anti-angiogenic agents.
• Discussion of emerging therapies, including tyrosine kinase inhibitors and biosimilars.

Main Results:

• Bevacizumab has shown efficacy in various settings (first-line, second-line, maintenance).
• Sequential use of anti-angiogenic drugs (e.g., ramucirumab, aflibercept) after bevacizumab failure is established.
• New oral tyrosine kinase inhibitors show modest efficacy in late-stage trials.

Conclusions:

• Optimizing therapeutic sequencing of anti-angiogenic agents requires well-designed prospective randomized trials.
• The role of biosimilars in colorectal cancer treatment is currently undefined.
• Further research should focus on identifying predictive biomarkers and developing cost-efficient, clinically meaningful anti-angiogenic drugs.